- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
WALTHAM, Mass. and SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (Nasdaq: HOWL) and Ambros Therapeutics, Inc., The post Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement appeared first on Werewolf Therapeutics.
WATERTOWN, Mass., July 31, 2026 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) The post Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates appeared first on Werewolf Therapeutics.
WATERTOWN, Mass., May 7, 2026 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) The post Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates appeared first on Werewolf Therapeutics.
WATERTOWN, Mass., March 27, 2026 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) The post Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates appeared first on Werewolf Therapeutics.
WATERTOWN, Mass., February 24, 2026 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) The post Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives appeared first on Werewolf Therapeutics.
WATERTOWN, Mass., December 18, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) The post Werewolf Therapeutics Announces Pipeline and Business Updates appeared first on Werewolf Therapeutics.
WATERTOWN, Mass., November 7, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) The post Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting appeared first on Werewolf Therapeutics.
WATERTOWN, Mass., November 4, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) The post Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update appeared first on Werewolf Therapeutics.
WATERTOWN, Mass., October 8, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) The post Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer appeared first on Werewolf Therapeutics.
WATERTOWN, Mass., October 3, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) The post Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting appeared first on Werewolf Therapeutics.